Our Cancer Programs
For over 20 years, we’ve developed our cancer programs and expanded our partnerships to reach cancer patients in over 70 low- and middle-income countries. We now offer a wide portfolio of lifesaving medications for ten disease areas and growing.
CML ProgramChronic Myeloid Leukemia
- 74 countries
- 5 lines of medicine
GIST ProgramGastrointestinal Stromal Tumor
- 67 countries
- 2 lines of medicine
RCC ProgramRenal Cell Carcinoma
- 38 countries
- 3 lines of medicine
— Bunthan Kahn from Cambodia, CML patient on treatment since 2017, pictured with his son and wife
Access to Diagnostics
Before we can provide medicine to patients, we must know what it is we are treating. We support patients with diagnostic services in under-resourced settings. Early detection and ongoing monitoring allow patients to change medication when needed and stay ahead of the cancer’s spread.
- 13 Countries supported with access to diagnostics through our Solidarity Fund
- 3,130 PCR tests given to patients
— Dr. Mirzovali Rahimov, our partner physician leading the diagnostics access initiative in Tajikistan, where her team successfully confirmed a patient’s diagnosis for the first time in December, 2019
Access to Care & Support
Through our patient-centered approach, we counsel individuals through our patient services, providing emotional support, disease education, and connections to patient communities. Our regional team members help patients navigate myriad cultural implications—the largest factor being cancer and disease stigmatization.
- 120,000+ connections with patient communities worldwide, through emotional support, phone calls, group meetings, disease education, and advocacy.
— Tenaye Alazar, The Max Foundation Local Program Coordinator, Ethiopia